The phrase "leaky gut" has had an awkward journey through medicine. For years it was dismissed as alternative health nonsense. The kind of thing talked about at wellness retreats between sessions on crystal healing. Meanwhile, gastroenterologists, hepatologists, and immunologists were publishing research demonstrating that intestinal hyperpermeability, the precise, technical name for "leaky gut", is a real, measurable, clinically significant phenomenon with serious downstream consequences.

Consequences that include, increasingly clearly, liver disease.

The gut-liver axis is not a wellness concept. It is a physiological reality, and the research around it has exploded over the past two decades. This article is your guide to understanding what intestinal permeability actually is, what genuinely compromises it, how the liver pays the price, and, most importantly, what YOU can do about it.

What Is "Leaky Gut," Actually?

Your small intestinal lining performs one of the most remarkable jobs in the body. A single layer of epithelial cells: just one cell thick, serves as the barrier between the contents of your gut (food particles, digestive enzymes, and up to 100 trillion microorganisms) and your body's interior. Get the barrier wrong in either direction and you're in trouble: too tight and you can't absorb nutrients; too loose and you let in things that shouldn't be there.

The cells in this lining are held together by protein complexes called tight junctions. Specifically proteins including occludin, claudins, and zonula occludens (ZO-1).¹ When these junctions function normally, they create a selectively permeable barrier. When they break down through inflammation, infection, certain foods, toxins, or stress, the barrier becomes "leaky," allowing:

• Bacterial fragments particularly LPS from gram-negative bacteria
• Undigested food antigens like peptide fragments
• Bacterial toxins and metabolites
• Intact bacteria called bacterial translocation

...to pass from the gut lumen into the lamina propria and, critically, into the portal blood supply, directly to the liver.

This isn't a metaphor. It can be directly measured. The most common tests include the lactulose/mannitol ratio test (urinary excretion of these sugars after oral ingestion reflects paracellular permeability), serum zonulin levels (zonulin is a protein that regulates tight junction opening), and serum LPS or LPS-binding protein as markers of bacterial translocation.²

Early Warning Signs of Increased Intestinal Permeability

Intestinal hyperpermeability rarely announces itself with a single dramatic symptom. Instead, it tends to appear as a constellation of seemingly unrelated problems that gradually worsen. Here's what the research and clinical experience suggest:

Gut-Related Signs

• Chronic bloating: particularly after meals, not explained by specific food intolerances.
• Irritable bowel symptoms: alternating diarrhoea and constipation, cramping, urgency.
• Food sensitivities that seem to be multiplying: as the gut barrier loses integrity, more food antigens cross into immune territory, generating new reactions.
• Persistent digestive discomfort that doesn't resolve with standard dietary measures.
• Nausea and feeling unwell after eating.

Systemic and Immune Signs

• Chronic fatigue unrelated to sleep quality, likely driven by systemic immune activation from translocation of bacterial products.
• Brain fog and poor concentration. Neuroinflammation mediated by circulating cytokines from gut-derived LPS, which can activate microglia and disrupt blood-brain barrier integrity via TLR4 signalling.³
• Joint pain and inflammation: bacterial antigens circulating systemically may trigger or exacerbate autoimmune joint inflammation.
• Skin problems: eczema, psoriasis, and acne have all been linked to gut dysbiosis and increased intestinal permeability in human studies.⁴
• New or worsening allergies: loss of oral tolerance (the immune system's ability to "ignore" harmless food antigens) is partly dependent on an intact gut barrier.
• Autoimmune disease activity such as coeliac disease, inflammatory bowel disease, type 1 diabetes, multiple sclerosis, and Hashimoto's thyroiditis, have all been linked to intestinal hyperpermeability, with leaky gut implicated as a contributor to their development or severity.⁵

Signs That May Indicate the Liver Is Involved

• Elevated liver enzymes (ALT, AST) on blood work. Even mildly elevated levels deserve attention.
• Elevated GGT: particularly sensitive to hepatic inflammation and oxidative stress.
• Fatigue disproportionate to activity level.
• Nausea or intolerance of fatty foods reflects impaired bile production or flow.
• Upper right abdominal heaviness or tenderness.
• Elevated triglycerides and low HDL on lipid panels.
• Unexplained itching: bile salts depositing in skin when liver processing is impaired.
• Slightly jaundiced skin or eyes in more advanced cases. This warrants urgent medical evaluation.

Root Causes: What Actually Makes the Gut Leak?

1. The Modern Diet

Ultra-processed foods are the most pervasive driver of gut barrier dysfunction in the developed world. Several specific components are particularly damaging:

• Emulsifiers such as carboxymethylcellulose and polysorbate-80 are added to processed foods to improve texture and shelf life and have been shown in animal models to directly disrupt the mucus layer protecting the gut epithelium and alter microbiome composition in ways that promote intestinal inflammation.⁶ Human intervention studies have confirmed that dietary emulsifiers can alter gut microbiota composition.⁷
• Refined sugar and high-fructose corn syrup promote the growth of pathogenic bacteria and yeast (particularly Candida) while suppressing beneficial species, disrupting the symbiotic relationship that supports barrier function.
• Alcohol, even moderate consumption, is one of the most well-documented causes of intestinal hyperpermeability. Alcohol is metabolised in the gut to acetaldehyde, which directly disrupts tight junction proteins and increases oxidative stress in gut epithelial cells.⁸ The relationship between alcohol, leaky gut, and alcoholic liver disease is mechanistically foundational.
• Gluten in the context of coeliac disease triggers zonulin release, which opens tight junctions.⁹ In non-coeliac populations, the evidence for gluten increasing intestinal permeability is less settled but remains an active area of research.

2. Gut Dysbiosis and Reduced Microbial Diversity

The gut microbiome is integral to barrier function. Short-chain fatty acids (SCFAs), particularly butyrate, produced by beneficial bacteria fermenting dietary fiber are the primary energy source for colonocytes (colon cells) and are essential for maintaining tight junction integrity.¹⁰ Faecalibacterium prausnitzii, one of the most important SCFA producers, is consistently found at reduced levels in people with inflammatory bowel disease, NAFLD, and type 2 diabetes — conditions where intestinal permeability is elevated.¹¹

When beneficial species decline and pathogenic species proliferate (dysbiosis), the production of butyrate drops, the mucus layer thins, and the epithelial barrier weakens. This is why antibiotic overuse, which indiscriminately depletes beneficial bacteria, is associated with increased intestinal permeability and heightened risk of subsequent inflammatory and metabolic conditions.

3. Chronic Psychological Stress

The gut has its own nervous system: the enteric nervous system (ENS), containing more neurons than the spinal cord, and it is in constant bidirectional communication with the brain via the gut-brain axis.¹² Psychological stress activates the HPA axis and sympathetic nervous system, releasing corticotropin-releasing factor (CRF) which has been shown to directly increase intestinal permeability by acting on mast cells in the gut lining.¹³

This is not a minor effect. Animal studies show that psychological stress produces intestinal permeability changes measurable within hours; Human studies confirm that acute psychological stress, including public speech and examination stress, increases small intestinal permeability via CRH-mediated mast cell activation, and that post-traumatic stress disorder is independently associated with elevated circulating LPS and LPS-binding protein, markers of intestinal barrier dysfunction.¹⁴

4. Chronic NSAID Use

Non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen, aspirin and naproxen, are among the most commonly used medications worldwide. They directly damage the gut mucosa through two mechanisms: inhibition of prostaglandin synthesis (prostaglandins maintain mucus production and mucosal blood flow) and a topical cytotoxic effect on enterocytes.¹⁵ Chronic NSAID use is a well-established cause of small intestinal injury and increased permeability, separate from the gastric effects that receive more attention.

5. Infections and Dysbiosis-Triggering Events

Post-infectious gut permeability changes are documented. Acute gastroenteritis can disrupt the gut barrier and alter the microbiome in ways that persist for months to years after the infection resolves, a phenomenon central to post-infectious IBS and potentially relevant to the pathogenesis of SIBO (as discussed in our previous article).

6. Low-Grade Systemic Inflammation

This creates a chicken-and-egg situation: systemic inflammation (from obesity, autoimmune disease, metabolic syndrome) increases gut permeability, and increased gut permeability drives more systemic inflammation. Once established, this cycle is self-perpetuating.¹⁶

The Gut-Liver Axis: From Leaky Gut to Liver Disease

The relationship between intestinal permeability and liver disease has become one of the most actively researched areas in hepatology. Here's the mechanistic case:

Portal Vein: The Direct Line

All blood draining the gastrointestinal tract converges in the portal vein and flows directly to the liver. This means that anything crossing the gut epithelium like bacteria, LPS, undigested food antigens, microbial metabolites reaches the liver before it reaches any other organ. The liver is simultaneously the beneficiary of this design (it processes nutrients efficiently) and its greatest victim (it absorbs all the inflammatory consequences of gut barrier failure).

LPS, Toll-Like Receptors, and Hepatic Inflammation

LPS from gram-negative bacterial walls is, gram for gram, one of the most potent inflammogens in biology. When chronically elevated in portal blood, it binds to Toll-like receptor 4 (TLR-4) on hepatic Kupffer cells — the liver's resident macrophages. This triggers NFκB-mediated transcription of pro-inflammatory cytokines: TNF-α, IL-1β, IL-6, and IL-8.¹⁷

These cytokines are the drivers of the progression from simple hepatic steatosis (fat accumulation) to metabolic steatohepatitis (MASH/NASH), the inflammatory, damaging phase that can progress to fibrosis and cirrhosis.¹⁸ Put plainly: bacteria leaking through a compromised gut barrier appear to be fuelling the inflammatory fire in fatty liver disease.

Serum LPS-binding protein, a marker of LPS translocation, is elevated in patients with NAFLD and increases with disease severity.¹⁹ Zonulin, the gut permeability marker, is significantly elevated in patients with NAFLD compared to healthy controls.²⁰

The Two-Hit Model

The classical "two-hit hypothesis" of NASH proposed that:

1. Metabolic dysfunction (insulin resistance, obesity) causes hepatic steatosis (first hit)
2. A second hit: oxidative stress and inflammatory cytokines trigger progression to steatohepatitis.

Gut-derived LPS and microbial products are increasingly recognised as major sources of that "second hit".²¹ More contemporary models (the "multiple parallel hits" model) position gut dysbiosis and intestinal hyperpermeability as continuous contributors to disease progression, not merely a second event.

Alcoholic Liver Disease

The gut-liver axis in alcoholic liver disease (ALD) is perhaps the most mechanistically established. Alcohol directly increases intestinal permeability (as noted above), promotes Gram-negative bacterial overgrowth in the small intestine, and dramatically increases portal LPS delivery to the liver. Animal studies in which the portal vein is bypassed or LPS is neutralised show profound protection against alcohol-induced liver injury, demonstrating that gut-derived LPS is causally required for alcoholic hepatitis, not merely associated with it.²²

Cirrhosis and Bacterial Translocation

In established cirrhosis, the relationship between the gut and liver becomes critically dangerous. Portal hypertension (elevated pressure in the portal vein system) and compromised liver immunity compound gut barrier dysfunction, leading to significant bacterial translocation. Spontaneous bacterial peritonitis (bacterial infection of the fluid in the abdominal cavity), one of the most feared complications of cirrhosis, is caused by translocation of gut bacteria.²³

Preventing and managing gut permeability in cirrhosis is therefore not optional; it is central to survival.

Steps to Heal Both: The Evidence

Step 1: Remove the Barrier Disruptors

You can supplement and support all you like, but if the insults continue, healing is an uphill battle. The most important first steps are reducing:

• Ultra-processed foods, especially those with emulsifiers and artificial additives.
• Alcohol. Even a modest reduction has measurable benefits for gut barrier function.
• Unnecessary NSAIDs — paracetamol (acetaminophen) is less damaging to the gut lining as an alternative, though it carries its own hepatic considerations at high doses.
• Chronic psychological stress. This means implementing genuine stress reduction, not just "taking breaks".

Step 2: Feed the Beneficial Bacteria

A diverse, plant-rich diet is the most powerful tool for restoring microbiome health and SCFA production:

• Aim for 30+ different plant foods per week: the American Gut Project found this was the single strongest predictor of microbiome diversity.²⁴
• Fermented foods like yoghurt, kefir, kimchi, sauerkraut, tempeh can increase microbiome diversity and have been shown in an RCT to outperform high-fibre diets for microbiome diversity restoration.²⁵
• Prebiotic fibre like inulin, FOS and resistant starch, specifically feeds SCFA-producing bacteria like F. prausnitzii and Bifidobacterium species.

Step 3: Targeted Supplementation to Restore Barrier Integrity

The following have the most evidence for supporting tight junction function:

• L-Glutamine: The primary fuel source for enterocytes. Supplementation has been shown to reduce intestinal permeability in clinical settings, particularly in stress states and post-surgery.²⁶ A dose of 5–15g daily has been used in research settings.
• Zinc: Zinc deficiency directly impairs gut barrier function. Tight junction proteins are zinc-dependent. Zinc supplementation has been shown to restore intestinal permeability in zinc-deficient patients with alcoholic liver disease and Crohn's disease.²⁷
• Vitamin D: Vitamin D receptors are highly expressed in the gut epithelium, and vitamin D directly regulates the expression of tight junction proteins including claudin-1 and occludin. Vitamin D deficiency is associated with increased intestinal permeability and worsened IBD, NAFLD, and metabolic syndrome.²⁸
• Butyrate (sodium or calcium butyrate supplements): Providing butyrate directly — as a supplement, particularly as the enteric-coated form — can compensate for reduced endogenous production and support colonocyte energy and tight junction integrity.¹⁰
• Probiotics: Specific probiotic strains have demonstrated intestinal barrier-supporting effects in human clinical trials. Lactobacillus rhamnosus GG has been shown to improve intestinal permeability in a randomised, double-blind, placebo-controlled trial, alongside significant immune modulation. Multi-strain formulations including Bifidobacterium infantis and Lactobacillus plantarum 299v have shown additional preclinical and emerging clinical evidence for barrier support.²⁹

Step 4: Directly Support Liver Health

While healing the gut reduces the inflammatory load reaching the liver, additional liver support is evidence-based:

• Silymarin (milk thistle): A flavonoid complex with multiple mechanisms of hepatoprotection — antioxidant, anti-inflammatory, membrane-stabilising, and anti-fibrotic effects. A meta-analysis of 17 clinical trials found significant reductions in ALT and AST in patients with liver disease taking silymarin.³⁰
• Coffee consumption: Multiple large prospective studies have found inverse associations between coffee consumption and progression of liver disease, including NAFLD, fibrosis, and cirrhosis.³¹ The mechanism involves antioxidants in coffee, including chlorogenic acids, reducing hepatic inflammation and fibrosis. This is one of the most robust and replicable findings in hepatology.
• Omega-3 fatty acids: EPA and DHA reduce hepatic triglyceride accumulation, improve liver enzyme levels, and have anti-inflammatory effects in the liver via multiple pathways.³²
• Vitamin E (as tocopherol): An antioxidant shown in the PIVENS RCT to significantly improve histological features of NASH (including steatohepatitis) in non-diabetic adults. It remains one of the few supplements with RCT-level evidence for NASH.³³
• Avoid hepatotoxic exposures: Including high-dose paracetamol, certain herbal supplements (kava, comfrey, pennyroyal), and excessive fructose.

Step 5: Address the Metabolic Underpinning

For many people, intestinal hyperpermeability and liver disease exist in the context of metabolic syndrome, insulin resistance, or obesity. The strategies outlined in our companion article on PCOS and fatty liver apply directly here: weight reduction, blood glucose stabilisation, exercise, and, where appropriate, metformin.

Step 6: Manage Stress as Medicine

Given the direct pathway between HPA activation and gut permeability, stress management is not optional supportive care — it is mechanistically justified treatment. Interventions with evidence:

• Mindfulness-based stress reduction (MBSR): Has been shown in RCTs to reduce gut symptoms and markers of inflammation.
• Regular exercise: Independently improves gut microbiome diversity and reduces systemic inflammation.³⁴
• Sleep optimisation: Sleep deprivation is associated with gut microbiome disruption and reduced microbial diversity. Animal models consistently show increased intestinal permeability with sleep deprivation, and in humans, circadian rhythm disruption is mechanistically linked to gut barrier dysfunction via HPA axis activation and CRF signalling, the same pathway that drives stress-induced permeability increases.³⁵

Monitoring Progress

How do you know if the gut-liver axis is healing? Markers to track with your doctor:

• Liver function tests ALT, AST or GGT should trend down with effective treatment.
• Fasting triglycerides: a sensitive metabolic marker.
• High-sensitivity CRP (hs-CRP): a marker of systemic inflammation.
• Serum 25-OH vitamin D: checking adequacy and supplementing to optimise.
• Symptom tracking: bloating frequency and severity, bowel regularity, energy and cognition.

For those who want to dig deeper, hepatic elastography (FibroScan) is a non-invasive way to assess liver stiffness (a proxy for fibrosis) and hepatic fat content, widely available at gastroenterology centres.

When This Is Urgent

Some signs require prompt medical attention, not a dietary protocol:

• Jaundice: yellowing of skin or eyes.
• Ascites: abdominal fluid accumulation which causes abdominal distension that doesn't resolve, associated with flank fullness.
• Easy bruising or prolonged bleeding: impaired liver synthesis of clotting factors.
• Mental confusion or personality change: hepatic encephalopathy.
• Dark urine and pale stools: biliary obstruction.

These signs indicate advanced liver disease requiring urgent specialist assessment.

The gut and the liver are not separate organs with separate problems. They are partners in a continuous, high-stakes relationship. The research of the past two decades has made clear that when the gut barrier fails, the liver is the first to suffer the consequences.

"Leaky gut" is real. It is measurable. It has identifiable causes, most of which are modifiable. And there are evidence-based strategies to restore barrier integrity and reduce the inflammatory burden on the liver, stacking the deck in favour of recovery.

The path forward is not complicated, but it is comprehensive. It involves what you eat, how you manage stress, what you supplement, how you sleep, and how often you move. None of those things are alternative medicine. They are the applied science of how human physiology actually works.

Start there.

References

1. Turner JR. Intestinal mucosal barrier function in health and disease. Nat Rev Immunol. 2009;9(11):799–809. PMID: 19855405
2. Michielan A, D'Incà R. Intestinal permeability in inflammatory bowel disease: pathogenesis, clinical evaluation, and therapy of leaky gut. Mediators Inflamm. 2015;2015:628157. PMID: 26582965
3. Geng S, Zheng Y, Meng M, et al. Gut microbiome-gut-brain axis and neuroinflammation. Front Cell Infect Microbiol. 2022;12:1000050. PMID: 36619762
4. Salem I, Ramser A, Isham N, Ghannoum MA. The gut microbiome as a major regulator of the gut-skin axis. Front Microbiol. 2018;9:1459. PMID: 30042740
5. Fasano A. Leaky gut and autoimmune diseases. Clin Rev Allergy Immunol. 2012;42(1):71–78. PMID: 22109896
6. Chassaing B, Koren O, Goodrich JK, et al. Dietary emulsifiers impact the mouse gut microbiota promoting colitis and metabolic syndrome. Nature. 2015;519(7541):92–96. PMID: 25731162
7. Chassaing B, Van de Wiele T, De Bodt J, et al. Dietary emulsifiers directly alter human microbiota composition and gene expression ex vivo potentiating intestinal inflammation. Gut. 2017;66(8):1414–1427. PMID: 27553064
8. Bishehsari F, Magno E, Swanson G, et al. Alcohol and gut-derived inflammation. Alcohol Res. 2017;38(2):163–171. PMID: 28988571
9. Fasano A. Zonulin and its regulation of intestinal barrier function: the biological door to inflammation, autoimmunity, and cancer. Physiol Rev. 2011;91(1):151–175. PMID: 21248165
10. Peng L, Li ZR, Green RS, et al. Butyrate enhances the intestinal barrier by facilitating tight junction assembly via activation of AMP-kinase in Caco-2 cell monolayers. J Nutr. 2009;139(9):1619–1625. PMID: 19625695
11. Sokol H, Pigneur B, Watterlot L, et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci USA. 2008;105(43):16731–16736. PMID: 18936492
12. Furness JB. The enteric nervous system and neurogastroenterology. Nat Rev Gastroenterol Hepatol. 2012;9(5):286–294. PMID: 22392290
13. Söderholm JD, Perdue MH. Stress and the gastrointestinal tract II. Stress and intestinal barrier function. Am J Physiol Gastrointest Liver Physiol. 2001;280(1):G7–G13. PMID: 11123193
14. Vanuytsel T, van Wanrooy S, Vanheel H, et al. Psychological stress and corticotropin-releasing hormone increase intestinal permeability in humans by a mast cell-dependent mechanism. Gut. 2014;63(8):1293–1299. PMID: 24153250
15. Maiden L, Thjodleifsson B, Theodors A, Gonzalez J, Bjarnason I. A quantitative analysis of NSAID-induced small bowel pathology by capsule enteroscopy. Gastroenterology. 2005;128(5):1172–1178. PMID: 15887101
16. Cani PD, Amar J, Iglesias MA, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes. 2007;56(7):1761–1772. PMID: 17456850
17. Szabo G, Csak T. Inflammasomes in liver diseases. J Hepatol. 2012;57(3):642–654. PMID: 22634126
18. Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology. 2010;52(5):1836–1846. PMID: 21038418
19. Verdam FJ, Rensen SS, Driessen A, et al. Novel evidence for chronic exposure to endotoxin in human nonalcoholic steatohepatitis. J Clin Gastroenterol. 2011;45(2):149–152. PMID: 20697306
20. Miele L, Valenza V, La Torre G, et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology. 2009;49(6):1877–1887. PMID: 19358219
21. Day CP, James OF. Steatohepatitis: a tale of two "hits"? Gastroenterology. 1998;114(4):842–845. PMID: 9547102
22. Szabo G. Gut-liver axis in alcoholic liver disease. Gastroenterology. 2015;148(1):30–36. PMID: 25447847
23. Wiest R, Garcia-Tsao G. Bacterial translocation (BT) in cirrhosis. Hepatology. 2005;41(3):422–433. PMID: 15723320
24. McDonald D, Hyde E, Debelius JW, et al. American Gut: an open platform for citizen science microbiome research. mSystems. 2018;3(3):e00031-18. PMID: 29795809
25. Wastyk HC, Fragiadakis GK, Perelman D, et al. Gut-microbiota-targeted diets modulate human immune status. Cell. 2021;184(16):4137–4153. PMID: 34256014
26. Coeffier M, Déchelotte P. The role of glutamine in intensive care unit patients: mechanisms of action and clinical outcome. Nutr Rev. 2005;63(2):65–69. PMID: 15762090
27. Zhong W, McClain CJ, Cave M, et al. The role of zinc deficiency in alcohol-induced intestinal barrier dysfunction. Am J Physiol Gastrointest Liver Physiol. 2010;298(5):G625–G633. PMID: 20167873
28. Kong J, Zhang Z, Musch MW, et al. Novel role of the vitamin D receptor in maintaining the integrity of the intestinal mucosal barrier. Am J Physiol Gastrointest Liver Physiol. 2008;294(1):G208–G216. PMID: 17962355
29. Sindhu KNC, Sowmyanarayanan TV, Paul A, et al. Immune response and intestinal permeability in children with acute gastroenteritis treated with Lactobacillus rhamnosus GG: a randomized, double-blind, placebo-controlled trial. Clin Infect Dis. 2014;58(8):1107–1115. PMID: 24501384
30. Gillessen A, Schmidt HH. Silymarin as supportive treatment in liver diseases: a narrative review. Adv Ther. 2020;37(4):1279–1301. PMID: 32006251
31. Kennedy OJ, Roderick P, Buchanan R, et al. All coffee types decrease the risk of adverse clinical outcomes in chronic liver disease: a UK Biobank study. BMC Public Health. 2021;21(1):970. PMID: 34039318
32. Scorletti E, Bhatia L, McCormick KG, et al. Effects of purified eicosapentaenoic and docosahexaenoic acids in nonalcoholic fatty liver disease: results from the Welcome* study. Hepatology. 2014;60(4):1211–1221. PMID: 25043514
33. Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis (PIVENS trial). N Engl J Med. 2010;362(18):1675–1685. PMID: 20427778
34. Mailing LJ, Allen JM, Buford TW, et al. Exercise and the gut microbiome: a review of the evidence, practical applications, and future directions. Exerc Sport Sci Rev. 2019;47(2):75–85. PMID: 30883471
35. Karl JP, Wilson MA, Radcliffe PN, et al. Severe, short-term sleep restriction reduces gut microbiota community richness but does not alter intestinal permeability in healthy young men. Sci Rep. 2023;13(1):213. PMID: 36604516

This article is for informational and educational purposes only and does not constitute medical advice. Please consult a qualified healthcare provider for diagnosis and treatment.